--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-24-027958" form_type: "8-K" ticker: null cik: "0001061027" company_name: "Viracta Therapeutics, Inc." filed_at: "2024-03-07T23:59:59+00:00" generated_at: "2026-06-05T01:05:24.017483+00:00" event_type: "earnings" sentiment: "neutral" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # Viracta reports Q4 2023 net loss of $13.8M; cash $53.7M; NAVAL-1 enrollment complete; runway extended to mid-Q1 2025 ## Summary - Net loss Q4 2023 $13.8M ($0.35/sh) vs $10.3M ($0.27) Q4 2022; full year $51.1M ($1.32) vs $49.2M ($1.30). - Cash and short-term investments $53.7M at Dec 31, 2023; pro forma cash runway extended into mid-Q1 2025 via $5M prepayment and loan amendments. - Received $5M non-dilutive from Day One biopharma for milestone monetization; amended SVB-Oxford loan with $5M prepayment, interest-only through June 2024. - Completed Stage 2 enrollment in NAVAL-1 trial for R/R EBV+ PTCL; Stage 1 topline data expected Q2 2024; FDA engagement mid-2024 for accelerated approval. - Phase 1b/2 solid tumor study completed sixth dose cohort; RP2D expected H2 2024; ODD granted for nasopharyngeal carcinoma in December 2023. ## SEC filing metadata - accession: 0000950170-24-027958 - form_type: 8-K - cik: 0001061027 - company_name: Viracta Therapeutics, Inc. - filed_at: 2024-03-07T23:59:59+00:00 - event_type: earnings - sentiment: neutral - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 1.01, 2.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027958/0000950170-24-027958-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027958/virx-20240301.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-24-027958 - JSON: https://secwatch.observer/filing/0000950170-24-027958.json - Plain text: https://secwatch.observer/filing/0000950170-24-027958.txt ## Key facts - Earnings Releases Viracta Therapeutics, Inc. reported financial results for fourth quarter and full-year of 2023. - Period: fourth quarter and full-year of 2023 - Result: reported results source text: On March 7, 2024, Viracta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended December 31, 2023. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027958/0000950170-24-027958-index.htm - Material Agreements Viracta Therapeutics, Inc. amended Amendment No. 1 (the “XOMA Amendment”) to the Royalty Purchase Agreement with XOMA (US) LLC valued at $5.0 million (effective 2024-03-04). - Action: amendment - Counterparty: XOMA (US) LLC - Value: $5.0 million - Effective: 2024-03-04 source text: On March 4, 2024, in connection with the entry into the Day One Amendment, the Company entered into an Amendment No. 1 (the “XOMA Amendment”) to the Royalty Purchase Agreement, dated as March 22, 2021, by and between the Company and XOMA (US) LLC, modifying the economic value-share under the Royalty Purchase Agreement, by which the Company has retained the right, under certain circumstances, to participate in a pre-commercialization, event-based milestone up to $5.0 million. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027958/0000950170-24-027958-index.htm - Material Agreements Viracta Therapeutics, Inc. amended Second Amendment (the “Second Amendment”) to the Loan and Security Agreement with Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company, and Oxford Finance LLC valued at $5.0 million (effective 2024-03-01). - Action: amendment - Agreement: credit facility - Counterparty: Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company, and Oxford Finance LLC - Value: $5.0 million - Effective: 2024-03-01 source text: On March 1, 2024, the Company entered into a Second Amendment (the “Second Amendment”) to the Loan and Security Agreement by and among the Company and Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company, and Oxford Finance LLC, dated November 4, 2021, as previously amended, providing for a modification of the loan amortization period and a pro rata reduction in the prospective debt amortization schedule, in exchange for a partial prepayment of the term loan. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027958/0000950170-24-027958-index.htm - Material Agreements Viracta Therapeutics, Inc. amended Amendment No. 1 (the “Day One Amendment”) to the License Agreement for RAF with Day One Biopharmaceuticals, Inc., successor in interest to DOT Therapeutcs-1, Inc. valued at $5.0 million (effective 2024-03-04). - Action: amendment - Agreement: license - Counterparty: Day One Biopharmaceuticals, Inc., successor in interest to DOT Therapeutcs-1, Inc. - Value: $5.0 million - Effective: 2024-03-04 source text: On March 4, 2024, the Company entered into an Amendment No. 1 (the “Day One Amendment”) to the License Agreement for RAF, dated as of December 16, 2019, by and between the Company and Day One Biopharmaceuticals, Inc., successor in interest to DOT Therapeutcs-1, Inc., to monetize a pre-commercialization, event-based milestone for $5.0 million to be received in March 2024, thereby reducing the milestone percentage under the agreement. evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027958/0000950170-24-027958-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.